EMA Grants Orphan Drug Designation to Kedrion's Ceruloplasmin Treatment for Rare Iron Metabolism Disorder
Key Insights
The European Medicines Agency (search) has granted Orphan Drug Designation to Kedrion's investigational plasma-derived treatment for Congenital Aceruloplasminemia (search), a rare genetic disorder affecting iron metabolism.
Aceruloplasminemia (search) causes iron accumulation in the brain, liver, and pancreas, leading to severe neurological symptoms (search), diabetes (search), anemia (search), and retinal degeneration (search) without effective treatment options.
Kedrion's innovative approach transforms unused plasma fractionation intermediates into potential therapies, supported by recent publications in Nature Communications Biology and Lancet eBioMedicine.
The European Medicines Agency (search) (EMA) has granted Orphan Drug Designation to Kedrion Biopharma (search)'s investigational treatment for Congenital Aceruloplasminemia (search) (ACP), marking a significant advancement for patients with this rare genetic disorder of iron metabolism. The designation follows a recent similar approval from the FDA, highlighting the global recognition of this therapeutic approach.
Addressing an Ultra-Rare Genetic Disorder
Aceruloplasminemia (search) is an autosomal recessive disorder caused by mutations in the CP gene (search), leading to a deficiency or absence of Ceruloplasmin, a key plasma protein essential for iron transport. Without treatment, iron accumulates in the brain, liver, and pancreas, causing severe neurological symptoms (search), diabetes (search), anemia (search), and retinal degeneration (search). Patients with this devastating ultra-rare and neurodegenerative condition currently have no approved drug options available.
Innovative Plasma-Derived Approach
Kedrion's treatment represents a novel approach to rare disease therapy development by pioneering the use of unused plasma fractionation intermediates. This method transforms what would otherwise be industrial plasma waste into potential new treatments, optimizing the use of precious plasma resources while advancing sustainability in biopharmaceutical innovation.
"This designation from EMA, following the recent Orphan Drug Designation granted by the FDA, is a further validation of our science-driven approach to rare and ultra-rare disease innovation," said Andrea Caricasole, Chief R&D and Innovation Officer at Kedrion. "By unlocking the therapeutic potential of this protein, we aim to address Aceruloplasminemia (search), a devastating ultra-rare and neurodegenerative condition that lacks effective options."
Scientific Foundation and Collaborative Support
The development is supported by the Italian Ministry for Enterprises and Made in Italy (search) (MIMIT) through the research project named "NATURAL," which aims to foster research for new therapies by leveraging unused plasma fractionation intermediates. The milestone results from collaborative efforts with academic and clinical partners.
Recent scientific publications have provided strong evidence for the approach. A study published in Nature Communications Biology (2024) demonstrated the feasibility of purifying Ceruloplasmin from unused plasma fractionation intermediates and its therapeutic efficacy in preclinical models of Aceruloplasminemia (search). Additionally, research published in Lancet eBioMedicine (2025) provided functional insights into missense variants of the Ceruloplasmin gene and assessed the real-world prevalence of Aceruloplasminemia using population-level data.
Clinical Development Path Forward
Kedrion plans to continue advancing this treatment toward clinical development in Europe, with the goal of enabling timely access for patients who currently have no effective treatment options. The company's commitment extends beyond this single indication, as it continues to develop plasma-derived therapies for rare, ultra-rare, and debilitating conditions including coagulation and neurological disorders, immunodeficiencies, and Rh sensitization.
The orphan drug designation provides Kedrion with regulatory incentives including market exclusivity, protocol assistance, and reduced fees, facilitating the development pathway for this much-needed therapy. For patients with Aceruloplasminemia (search), this milestone represents a concrete step forward in the future availability of a new therapy for a condition that has long lacked effective treatment options.